https://pharmaphorum.com/news/ucb-brings-first-therapy-rare-disease-tk2d-eu
UCB brings first therapy for rare disease TK2d to EU | pharmaphorum
The EU has approved UCB's Kygevi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
rare diseaseucbbringsfirsttherapy